Zydus Lifesciences Limited · NSE:ZYDUSLIFE

Zydus Lifesciences — Cadila Healthcare — Investor Presentation (May 2015)

16 slides from Zydus Lifesciences's investor presentation, May 2015

  1. Slide 1: Cadila Healthcare Limited Investor Presentation

    Cadila Healthcare Limited Investor Presentation May 2015

  2. Slide 2: Well integrated pharma player with global footprints

    Well integrated pharma player with global footprints >60 years ~ $ 1.4 bn ~ 7% of sales Operational Global Revenues Spent on R&D annually experience 20+ mfg. sites >18% CAGR 1st Indian Company In Gross Sales and To discover & develop Producing >15 Net Profits an NCE in-house : bn pills annually (FY

  3. Slide 3: History of achieving milestones consistently

    History of achieving milestones consistently 43 fold growth in sales over last 20 years… …with significant external recognition CNBC – TV 18 India innovator Award 2013 Economic Times Emerging Rs. 200 cr. Company of the year 2010 in 1995 3

  4. Slide 4: Key businesses for our journey Beyond the Billion

    Key businesses for our journey Beyond the Billion Zydus Established home Future home New Technology Other Businesses markets markets businesses ▪ US formulations ▪ Brazil ▪ EU ▪ Biosimilars ▪ India formulations ▪ Mexico ▪ Emerging markets ▪ Vaccines ▪ Wellness ▪ NCEs ▪ Animal Health ▪ APIs ▪ JVs & a

  5. Slide 5: Key Financial Numbers – FY 2014-15

    Key Financial Numbers – FY 2014-15 Consolidated (Rs. Mio.) Amount Gr.% Segment-wise Gross Sales Gross Sales 86,577 20.1% Total Income from Operations 86,513 19.8% India Form., 31% EBIDT 17,557 46.3% JVs ,5% EBIDT % to Income from Ops. 20.3% APIs, 4% Profit before tax 14,455 53.4% Animal Health, 4% U

  6. Slide 6: US formulations

    US formulations Market size* : ~$ 60 bn Aspirations Market growth* : 10%+ Zydus size** : ~ $ 557 mn  Be amongst the top 10 generic cos. in US with Zydus growth** : 53% continued strong focus on customer needs  One of the significant contributors to revenues and profits 32%+ CAGR in Sales (Last 5 y

  7. Slide 7: India formulations

    India formulations Aspirations Market size* : Rs. 860 bn+ Market growth* : 13%  Leadership in CVS, female healthcare and respiratory Zydus size** : Rs. 36 bn+ area, among top 5 players in GI and derma Market Share* : 4.22% Zydus growth** : 8%  Continue to be one of the significant contributors to

  8. Slide 8: Latin America Formulations - Brazil

    Latin America Formulations - Brazil Market size* : ~ $ 25 bn+ Aspirations Market growth* : 10%+ Zydus size** : Rs. 2,348 mn  To establish strong base with aggressive product Zydus growth** : - 5% launches. Strengths to be leveraged  Presence in branded generics and generic generics segments with a

  9. Slide 9: Latin America Formulations - Mexico

    Latin America Formulations - Mexico Market size* : ~ US$ 9 bn Aspirations Market growth* : - 4% Zydus size** : Rs. 2,348 mn Zydus growth** : - 5%  To establish strong base with aggressive product launches. Strengths to be leveraged  Focused therapeutic areas (Branded) – CNS and CVS  Launched 2 di

  10. Slide 10: Other Global Markets

    Other Global Markets Aspirations : To be a relevant player in these generics markets EU  Among top 10 in France, among top 20 in Spain Mkt. Size* : ~$ 6.5 bn  Expansion through new products : launched 140+ molecules in France (France + Spain Gx) and 100+ molecules in Spain so far (incl. several ‘D

  11. Slide 11: Other Businesses

    Other Businesses Wellness Aspirations : To create niches in wellness space through innovation  Leadership in sugar substitutes (~93% market share) and peel-off and scrub range for skin-care in India Zydus Size **:  Launched several new products under EverYuth brand.Upgraded Nutralite Rs. 4,430 mn

  12. Slide 12: Joint Ventures and Alliances

    Joint Ventures and Alliances Aspirations : Value creation through win-win alliances and be a partner of choice Zydus Takeda JV Zydus Hospira JV  State-of-the-art mfg. facility for APIs of  State-of-the-art cytotoxic facility approved Nycomed by leading authorities like MHRA, USFDA,  Commissioned

  13. Slide 13: Biosimilars and Vaccines

    Biosimilars and Vaccines Aspirations : Leverage technological edge to unlock substantial value and create pillars for future growth. Strengths to be leveraged Biosimilar pipeline Pre- Regulatory Mktg. Process Clinical No Product Indication Cloning Clinical Permissio Authori- Biosimilars Devp. Devp.

  14. Slide 14: NCE research

    NCE research Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020 Key strengths NCE Pipeline  State-of-the art Lead Pre- Drug clinical research facility Project Target Indication Discovery optimi- Develop- IND Phase I Phase II Phase III NDA saiton 

  15. Slide 15: World class infrastructure to support growth journey

    World class infrastructure to support growth journey Formulations Mfg. Oral Solids (India) Oral Solids Other dosage forms  Ahmedabad (USFDA ) (outside India) (India)  Baddi (USFDA)  US (Nesher Pharma –  Transdermals – controlled substances) Ahmedabad SEZ  Goa  Brazil  Topicals & Vaccines  Si

  16. Slide 16: Thank You. Safe Harbour Statement

    Thank You. Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also

Cadila Healthcare — Investor Presentation (May 2015) on 6ix